Management of patients with nephrotic syndrome

Swiss Medical Weekly

Volumn 139, Issue 29-30, 2009, Pages 416-422

  De Seigneux, Sophie ^a   Martin, Pierre Yves ^a  

^a HUG   (Switzerland)

Author keywords

Hypertension; Kidney; Nephrotic syndrome; Oedema; Proteinuria

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; VERAPAMIL; VITAMIN D;

ANEMIA; BONE METABOLISM; DIABETES MELLITUS; EDEMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPIDEMIA; HYPOALBUMINEMIA; INFECTION RISK; KIDNEY BIOPSY; KIDNEY FAILURE; LIPID BLOOD LEVEL; MINERAL METABOLISM; NEPHROTIC SYNDROME; PROTEIN URINE LEVEL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY HYPERPARATHYROIDISM; SODIUM RETENTION; THROMBOEMBOLISM; VITAMIN DEFICIENCY; WATER RETENTION;

EID: 68049113663     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Ruggenenti P, Gaspari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ. 1998;316(7130):504-509 (Pubitemid 28120955)
2. Cattran DC, Pei Y, Greenwood CM, Ponticelli C, Passerini P, Honkanen E. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int. 1997;51(3):901-907 (Pubitemid 27157980)
3. Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol. 2008;3(3):905-919
4. Breyer JA, Bain RP, Evans JK, et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int. 1996;50 (5):1651-1658
5. Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol. 2005;16(7):2170-2179 (Pubitemid 41716450)
6. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006;116(2):288-296 (Pubitemid 43228342)
7. de ZD, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65(6):2309-2320 (Pubitemid 38670018)
8. Keane WF, Zhang Z, Lyle PA, et al. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol. 2006;1(4):761-767
9. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int. 1998;53(5):1209-1216
10. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-1559
11. Catapano F, Chiodini P, De NL, et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis. 2008;52(3):475-485
12. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70(3):536-542 (Pubitemid 44141580)
13. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543-551
14. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008; 358(23):2433-2446 (Pubitemid 351793017)
15. Alavi N, Lianos EA, Venuto RC, Mookerjee BK, Bentzel CJ. Reduction of proteinuria by indomethacin in patients with nephrotic syndrome. Am J Kidney Dis. 1986;8(6):397-403. (Pubitemid 17031991)
16. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428
17. Mansy H, Goodship TH, Tapson JS, Hartley GH, Keavey P, Wilkinson R. Effect of a high protein diet in patients with the nephrotic syndrome. Clin Sci. (Lond) 1989;77(4):445-451
18. Giordano M, De FP, Lucidi P, et al. Effects of dietary protein restriction on fibrinogen and albumin metabolism in nephrotic patients. Kidney Int. 2001;60(1):235-242 (Pubitemid 32587559)
19. Deschenes G, Wittner M, Stefano A, Jounier S, Doucet A. Collecting duct is a site of sodium retention in PAN nephrosis: a rationale for amiloride therapy. J Am Soc Nephrol. 2001;12(3):598-601. (Pubitemid 32180030)
20. Trevisan R, Dodesini AR, Lepore G. Lipids and renal disease. J Am Soc Nephrol. 2006;17(4 Suppl 2):S145-S147.
21. D'Amico G. Statins and renal diseases: from primary prevention to renal replacement therapy. J Am Soc Nephrol. 2006;17(4 Suppl 2):S148-S152.
22. Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol. 2007;18(8):2221-2225 (Pubitemid 47203835)
23. Sarasin FP, Schifferli JA. Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int. 1994;45(2):578-585 (Pubitemid 24065096)
24. Mahr N, Neyer U, Prischl F, et al. Proteinuria and hemoglobin levels in patients with primary glomerular disease. Am J Kidney Dis. 2005;46(3):424-431 (Pubitemid 41208177)
25. Elder GJ. Nephrotic syndrome: don't forget the bones! Nephrology. (Carlton ) 2008;13(1):43-44